Innovative Cold Sore Treatment Device Virulite Comes To US

Main Category: Dermatology
Article Date: 21 Jan 2008 - 5:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  


Current Article Ratings:

Patient / Public:5 stars

5 (3 votes)

Healthcare Prof:5 stars

4.56 (9 votes)


Virulite, LLC, a medical device manufacturer dedicated to developing the market for an innovative new treatment for cold sores, announced that it has retained Compass Point Capital, Inc. and Murphy Business and Financial Corporation as its mergers and acquisitions advisors.

Virulite, LLC has validated the US market for the Virulite device by successfully completing clinical trials and is presently in the process of obtaining FDA clearance. The Virulite product is successful in the UK and is both approved by the British National Health Service and CE marked.

The Virulite product, (patents granted and pending), is a portable, hand held device that uses an invisible, non-thermal band of near-infrared light. Virulite was developed in the UK after ten years of research and development, and has been medically proven in independent clinical trials to reduce the healing time of cold cores by up to one half.

The company completed a US market test of the product through Walgreen's online distribution channel, where Virulite outsold all competing cold sore remedies, including the current market leader, the topical cream Abreva by GlaxoSmithKline (GSK). In addition, Virulite received numerous customer testimonials from users who experienced astonishing results. Virulite, LLC recognizes the product requires a home with an established pharmaceutical, health product or medical device company in order to effectively penetrate the estimated $4 billion cold sore remedy market, and is actively seeking suitors.

About Virulite, LLC

Virulite LLC is focused on developing consumer markets using the Virulite 1072 nanometer technology. While the cold sore treatment is proven, the technology also has shown anecdotal success in treating genital herpes, bacterial infections and warts (clinical trials are underway for the latter two).

http://www.virulite.com

About Compass Point Capital, Inc. and Murphy Business and Financial Corporation

Compass Point is a leading west coast mergers and acquisition firm specializing in middle market companies and will be working with Murphy Business, one of the largest business sales organizations with offices nationwide. For more information, visit http://www.compasspointcapital.com and http://www.murphybusiness.com.


View drug information on ABREVA.


Article adapted by Medical News Today from original press release.
Visit our dermatology section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Virulite, LLC. "Innovative Cold Sore Treatment Device Virulite Comes To US." Medical News Today. MediLexicon, Intl., 21 Jan. 2008. Web.
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/94627.php>

APA
Virulite, LLC. (2008, January 21). "Innovative Cold Sore Treatment Device Virulite Comes To US." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/94627.php.

Please note: If no author information is provided, the source is cited instead.




Dermatology

Most Popular Articles



Follow Our Dermatology News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Dermatology Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »